ZA200409430B - Process for the manufacture of quinoline derivatives. - Google Patents

Process for the manufacture of quinoline derivatives.

Info

Publication number
ZA200409430B
ZA200409430B ZA200409430A ZA200409430A ZA200409430B ZA 200409430 B ZA200409430 B ZA 200409430B ZA 200409430 A ZA200409430 A ZA 200409430A ZA 200409430 A ZA200409430 A ZA 200409430A ZA 200409430 B ZA200409430 B ZA 200409430B
Authority
ZA
South Africa
Prior art keywords
manufacture
quinoline derivatives
formula
quinoline
chaineded
Prior art date
Application number
ZA200409430A
Other languages
English (en)
Inventor
Karl Jansson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of ZA200409430B publication Critical patent/ZA200409430B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200409430A 2002-06-12 2004-11-23 Process for the manufacture of quinoline derivatives. ZA200409430B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201778A SE0201778D0 (sv) 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives

Publications (1)

Publication Number Publication Date
ZA200409430B true ZA200409430B (en) 2006-02-22

Family

ID=20288148

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200409430A ZA200409430B (en) 2002-06-12 2004-11-23 Process for the manufacture of quinoline derivatives.

Country Status (28)

Country Link
EP (1) EP1511732B9 (fr)
JP (1) JP4584709B2 (fr)
KR (1) KR100979216B1 (fr)
CN (1) CN100418950C (fr)
AT (1) ATE348814T1 (fr)
AU (1) AU2003228195B2 (fr)
BR (1) BR0311674A (fr)
CA (1) CA2487329C (fr)
CY (1) CY1107555T1 (fr)
DE (1) DE60310554T2 (fr)
DK (1) DK1511732T5 (fr)
ES (1) ES2278160T3 (fr)
HR (1) HRP20050028B1 (fr)
IL (1) IL165155A (fr)
IS (1) IS2975B (fr)
ME (1) ME00435B (fr)
MX (1) MXPA04012276A (fr)
NO (1) NO329162B1 (fr)
NZ (1) NZ536768A (fr)
PL (1) PL210259B1 (fr)
PT (1) PT1511732E (fr)
RS (1) RS51021B (fr)
RU (1) RU2291861C2 (fr)
SE (1) SE0201778D0 (fr)
SI (1) SI1511732T1 (fr)
UA (1) UA78310C2 (fr)
WO (1) WO2003106424A1 (fr)
ZA (1) ZA200409430B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
CA2625287C (fr) 2005-10-19 2016-07-26 Teva Pharmaceutical Industries Ltd. Cristaux de sodium de laquinimod, et procede de fabrication de ceux-ci
ZA200810790B (en) * 2006-06-12 2010-03-31 Teva Pharma Stable laquinimod preparations
AU2007325629A1 (en) 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
EP2234485B1 (fr) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Préparations de laquinimod stables
KR20160079147A (ko) 2008-09-03 2016-07-05 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
EP2376456A2 (fr) * 2008-12-17 2011-10-19 Actavis Group Ptc Ehf Laquinimode très pur ou sel pharmaceutiquement acceptable de celui-ci
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
MX2012001333A (es) 2009-07-30 2012-06-01 Teva Pharma Tratamiento de la enfermedad de crohn con la laquinimod.
ES2586843T3 (es) 2009-08-10 2016-10-19 Teva Pharmaceutical Industries Ltd. Tratamiento de trastornos relacionados con BDNF usando laquinimod
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
AU2011223692A1 (en) 2010-03-03 2012-10-25 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod
SI2542079T1 (sl) 2010-03-03 2014-08-29 Teva Pharmaceutical Industries Ltd. Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata
PL2590949T3 (pl) * 2010-07-09 2016-06-30 Active Biotech Ab Sposób wytwarzania chinolino-3-karboksyamidów
EA025377B1 (ru) 2010-07-09 2016-12-30 Тева Фармасьютикал Индастриз Лтд. Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
MX2013000332A (es) * 2010-07-09 2013-02-26 Teva Pharma 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-dihidroquinolina-3-ca rboxamida, sales y usos de la misma.
EP2537517A1 (fr) * 2011-06-22 2012-12-26 Active Biotech AB 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide enrichie au deuterium
MX2014004420A (es) 2011-10-12 2014-07-09 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod.
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CN103626701A (zh) * 2012-08-28 2014-03-12 天津药物研究院 一种制备喹啉衍生物的方法
CN103626702A (zh) * 2012-08-30 2014-03-12 天津药物研究院 一种制备喹啉酮衍生物的方法
KR20150091077A (ko) 2012-11-07 2015-08-07 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드의 아민염
AU2014236232A1 (en) 2013-03-14 2015-11-05 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
CA2961978C (fr) 2014-09-23 2023-03-14 Active Biotech Ab Quinoleine carboxamides destinees a etre utilisees dans le traitement du myelome multiple
PL3180005T3 (pl) 2014-11-19 2018-06-29 Active Biotech Ab Chinolinokarboksyamidy do stosowania w leczeniu białaczki
IL295780A (en) 2020-03-03 2022-10-01 Active Biotech Ab Tesquinimov or a pharmaceutically acceptable salt thereof for use in combination therapy
CN111732540B (zh) * 2020-07-20 2020-11-13 湖南速博生物技术有限公司 一种罗喹美克的制备方法
JP2023535021A (ja) 2020-07-23 2023-08-15 イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム 骨髄増殖性腫瘍における新規治療用標的としてのｓ１００タンパク質
CA3204120A1 (fr) 2021-01-18 2022-07-21 Active Biotech Ab Tasquinomod ou sel pharmaceutiquement acceptable de celui-ci destine a etre utilise dans le traitement du syndrome myelodysplasique
AU2022281056A1 (en) 2021-05-25 2023-11-30 Active Biotech Ab A plurality of tasquinimod particles and use thereof
CA3221689A1 (fr) 2021-07-02 2023-01-05 Hans Wannman Produit pharmaceutique contenant du tasquinimod et procede d'evaluation de la purete dudit produit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
CN100418950C (zh) 2008-09-17
KR20050016537A (ko) 2005-02-21
RU2005100054A (ru) 2005-07-10
CA2487329C (fr) 2010-11-16
PT1511732E (pt) 2007-03-30
EP1511732A1 (fr) 2005-03-09
RU2291861C2 (ru) 2007-01-20
KR100979216B1 (ko) 2010-08-31
NO20045703L (no) 2004-12-29
CN1659146A (zh) 2005-08-24
MXPA04012276A (es) 2005-04-08
CA2487329A1 (fr) 2003-12-24
EP1511732B1 (fr) 2006-12-20
RS51021B (sr) 2010-10-31
DE60310554T2 (de) 2007-11-29
JP2005535612A (ja) 2005-11-24
ATE348814T1 (de) 2007-01-15
IS7550A (is) 2004-11-24
PL210259B1 (pl) 2011-12-30
BR0311674A (pt) 2008-01-08
RS107604A (en) 2007-02-05
JP4584709B2 (ja) 2010-11-24
DK1511732T5 (da) 2007-10-01
EP1511732B9 (fr) 2008-11-12
HRP20050028A2 (en) 2006-02-28
CY1107555T1 (el) 2013-03-13
HRP20050028B1 (hr) 2013-07-31
DK1511732T3 (da) 2007-04-30
IL165155A (en) 2009-11-18
IS2975B (is) 2017-07-15
ES2278160T3 (es) 2007-08-01
ME00435B (fr) 2011-10-10
UA78310C2 (en) 2007-03-15
WO2003106424A1 (fr) 2003-12-24
AU2003228195A1 (en) 2003-12-31
NO329162B1 (no) 2010-08-30
AU2003228195B2 (en) 2009-05-28
SI1511732T1 (sl) 2007-06-30
SE0201778D0 (sv) 2002-06-12
IL165155A0 (en) 2005-12-18
NZ536768A (en) 2006-10-27
PL373817A1 (en) 2005-09-19
DE60310554D1 (de) 2007-02-01

Similar Documents

Publication Publication Date Title
HRP20050028B1 (hr) Postupak za proizvodnju derivata kinolina
NO20055099L (no) Fremgangsmate for fremstilling av 5-(haloacetyl)-8-(substituert oksy)-(1H)-kinolin-2-oner
HUP0401647A2 (hu) Új béta-fenil-alfa-oxi-propionsav-származékok, előállítási eljárásaik és gyógyszerészetileg fontos vegyületek előállításánál történő felhasználásuk
CA2446944A1 (fr) Derives d'acides amines anti-inflammatoires et immunomodulateurs, leur preparation et leur utilisation
HUP0301699A2 (hu) Imidazolil-anilin-származékok előállítása anilinek és azolok racionális ligandum-gyorsított Ullmann-kapcsolásával
NO20044767L (no) Farmasoytisk formulering med modifisert frigjoring
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
DK1601653T3 (da) Fremgangsmåde til fremstilling af substituerede nikotinsyreestre
MY141020A (en) Novel pparalpha and ppargamma agonists
TW200720234A (en) Hydroxynaphthalenedicarboxylic acid hydrazide and derivatives thereof as well as process for preparing them
WO2003024913A1 (fr) Derives d'acides benzoiques substitues possedant une activite d'inhibition de nf-kb
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
NO20031046L (no) Fremgangsmåte for fremstilling av en substituert imidazopyridinforbindelse
AU5209600A (en) Orally active androgens
WO2003014094A3 (fr) Heterocyclylarylsulfonamides
WO2001083423A3 (fr) Acide 2,6-diamino-6-methyl-heptanoique et derives, procede de preparation et utilisation correspondants
MXPA05013715A (es) Proceso para preparar derivados del acido (2s)-3-(4- {2-[amino]-2 -oxoetoxi} fenil)-2- [amino]-2 -oxoetoxi}fenil)-2 -etoxipropanoico.
HUP0202335A2 (hu) Eljárás optikailag aktív, vinil-szubsztituált ciklopropánkarbonsavak racemizálására
TW200621807A (en) Cellulose derivative composition, cellulose derivative film and trialkoxybenzoic acid deriv ative compound
ES2184633A1 (es) Procedimiento para la preparacion de derivados de 4-(imidazol-1-il) bencenosulfonamida.
DE50110830D1 (de) Beschichtungen aus speziellen polyolen und oxalsäure
HUP0202296A2 (hu) Eljárás szubsztituált benzizotiazolszármazékok előállítására
NO20044045L (no) Ny fremgangsmate
TH72657A (th) สารประกอบ